Hostname: page-component-78c5997874-v9fdk Total loading time: 0 Render date: 2024-11-17T14:09:11.148Z Has data issue: false hasContentIssue false
  • English
  • Français

Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses

Published online by Cambridge University Press:  16 April 2020

Mathias Zink ,
Fritz A. Henn  and
Johannes Thome
Mathias Zink*
Affiliation:
Clinic of Psychiatry and Psychotherapy, Central Institute of Mental Health, P.O. Box 12 21 20, 68072Mannheim, Germany
Fritz A. Henn
Affiliation:
Clinic of Psychiatry and Psychotherapy, Central Institute of Mental Health, P.O. Box 12 21 20, 68072Mannheim, Germany
Johannes Thome
Affiliation:
Clinic of Psychiatry and Psychotherapy, Central Institute of Mental Health, P.O. Box 12 21 20, 68072Mannheim, Germany
*
*Corresponding author. E-mail address:[email protected] (M. Zink).
Get access

Abstract

Treatment-resistant schizophrenia often leads to combined application of antipsychotic drugs. We report first experience with the combination of olanzapine and amisulpride. Improvement of psychopathological state and side effects could be achieved, and drug doses were lower than under monotherapy. We thus conclude that this approach represents a useful therapeutic option.

Keywords

SchizophreniaAntipsychotic drugsAmisulprideOlanzapine
Type
Short communication
Information
European Psychiatry , Volume 19 , Issue 1 , January 2004 , pp. 56 - 58
Copyright
Copyright © 2003 European Psychiatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Caccia, S. Biotransformation of post-clozapine antipsychotics: pharmacological implications. Clin Pharmacokinet 2000;38(5):393–414.CrossRefGoogle ScholarPubMed
Conley, R.RMeltzer, H.Y. Adverse events related to olanzapine. J Clin Psychiatry 2000;61(Suppl 8):26–9 [discussion 30].Google ScholarPubMed
Freudenreich, OGoff, D.C. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323–30.CrossRefGoogle ScholarPubMed
Hellewell, J.S. Treatment-resistant schizophrenia: reviewing the options and identifying the way forward. J Clin Psychiatry 1999;60(Suppl 23):14–9.Google ScholarPubMed
Koshino, Y. Algorithm for treatment-refractory schizophrenia. Psychiatry Clin Neurosci 1999;53(Suppl):S9–S13.Google ScholarPubMed
Lecrubier, YAzorin, MBottai, TDalery, JGarreau, GLemperiere, Tet al. Consensus on the practical use of amisulpride, an atypical antipsychotic, in the treatment of schizophrenia. Neuropsychobiology 2001;44(1):41–6.CrossRefGoogle ScholarPubMed
Leucht, SPitschel-Walz, GEngel, R.RKissling, W. Amisulpride, an unusual “atypical” antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180–90.CrossRefGoogle ScholarPubMed
Ring, B.JBinkley, S.NVandenbranden, MWrighton, S.A. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes p450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br J Clin Pharmacol 1996;41(3):181–6.CrossRefGoogle ScholarPubMed
Stephenson, C.MPilowsky, L.S. Psychopharmacology of olanzapine. A review. Br J Psychiatry 1999;38(Suppl):52–8.CrossRefGoogle Scholar
Submit a response

Comments

No Comments have been published for this article.